News From Elixir Pharmaceuticals

A press release notes a new license and research direction. "Elixir Pharmaceuticals, Inc. announced today that it has licensed intellectual property [relating to] NaCT-1, a human ortholog of the longevity gene, INDY ... Our research suggests that aging is a carefully regulated metabolic process. The INDY gene product is an excellent example of an anti-aging target that has been proven to play a role in the cellular regulation of lipid and carbohydrate metabolism. ... a drug that inhibits NaCT-1 may provide a pharmacological means to reduce fat and cholesterol synthesis and thus enable control of [excess lipids, cholesterol and body fat] ... Elixir has an interest in the NaCT-1 transporter as a drug target for the development of pharmaceuticals to improve human health and prolong youthfulness."



Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.